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Abstract
Metabolism is critical for the mutagenicity, carcinogenicity, and other adverse health effects of 
trichloroethylene (TCE). Despite the relatively small size and simple chemical structure of TCE, 
its metabolism is quite complex, yielding multiple intermediates and end-products. Experimental 
animal and human data indicate that TCE metabolism occurs through two major pathways: 
cytochrome P450 (CYP)-dependent oxidation and glutathione (GSH) conjugation catalyzed by 
GSH S-transferases (GSTs). Herein we review recent data characterizing TCE processing and flux 
through these pathways. We describe the catalytic enzymes, their regulation and tissue 
localization, as well as the evidence for transport and inter-organ processing of metabolites. We 
address the chemical reactivity of TCE metabolites, highlighting data on mutagenicity of these 
end-products. Identification in urine of key metabolites, particularly trichloroacetate (TCA), 
dichloroacetate (DCA), trichloroethanol and its glucuronide (TCOH and TCOG), and N-acetyl-S-
(1,2-dichlorovinyl)-L-cysteine (NAcDCVC), in exposed humans and other species (mostly rats 
and mice) demonstrates function of the two metabolic pathways in vivo. The CYP pathway 
primarily yields chemically stable end-products. However, the GST pathway conjugate S-(1,2-
dichlorovinyl)glutathione (DCVG) is further processed to multiple highly reactive species that are 
known to be mutagenic, especially in kidney where in situ metabolism occurs. TCE metabolism is 
highly variable across sexes, species, tissues and individuals. Genetic polymorphisms in several of 
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the key enzymes metabolizing TCE and its intermediates contribute to variability in metabolic 
profiles and rates. In all, the evidence characterizing the complex metabolism of TCE can inform 
predictions of adverse responses including mutagenesis, carcinogenesis, and acute and chronic 
organ-specific toxicity.
Keywords
Cytochrome P450-dependent oxidation; glutathione conjugation; kidney; liver; reactive 
intermediates; trichloroethylene
1. Introduction: Summary of trichloroethylene (TCE) metabolism
TCE is a widespread environmental contaminant that has recently been classified as a 
human carcinogen by the International Agency for Research on Cancer (IARC) [1] and the 
U.S. Environmental Protection Agency (U.S. EPA) [2, 3]. TCE metabolism plays a critical 
role in eliciting its mutagenicity, carcinogenicity and other adverse health effects. Indeed, 
with the exception of non-specific solvent effects on the neurological system, most organ-
specific toxicity has been attributed to specific TCE metabolites. TCE metabolism occurs 
through two major pathways in humans and laboratory animals, cytochrome P450 (CYP)-
dependent oxidation and glutathione (GSH) conjugation [2-5]. Quantitatively, flux through 
the CYP-dependent oxidation pathway far exceeds that through the GSH conjugation 
pathway in all species studied, including humans. Metabolites generated by the CYP-
dependent oxidation pathway are mostly chemically stable. However, the GSH conjugation 
pathway generates several highly reactive metabolites that are known to be mutagenic. Due 
to this difference in the chemical reactivity of the resulting metabolites, interpretations 
regarding toxicological importance based on quantitative differences in estimated flux of 
TCE metabolism through these two pathways must be made with caution.
TCE metabolism to mutagenic and toxic moieties remains a significant consideration for 
predicting and interpreting carcinogenic and other adverse responses to TCE. Additionally, 
key urinary metabolites from these pathways have utility for estimating exposure in 
environmental or occupational settings. For example, the American Conference of 
Governmental and Industrial Hygienists (ACGIH) recommends the use of urinary 
trichloroacetate (TCA) levels at the end of the work week as a metric for assessing 
occupational TCE exposure [6]; they recommend a limit of 100 mg TCA/l.
While the basic outlines of the two TCE metabolism pathways depicted in Figs. 1 and 2 
have been known for many years [7], additional characterization of metabolites in the past 
decade has greatly expanded the understanding of TCE metabolism. The sections that follow 
emphasize recently described metabolites and briefly summarize the major pathways of TCE 
metabolism, the resulting metabolites, and the enzymes involved. Information on the 
genotoxic potential of TCE metabolites is highlighted. Inter-organ distribution of TCE 
metabolites as depicted in Fig. 3 is also discussed. Important sources of variability in TCE 
metabolism, both within and across species, are identified. The chemical nature and 
reactivity of TCE metabolites are important determinants of target organ mutagenicity and 
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tissue, sex, species, and individual differences in catalytic enzyme activity influence the 
resulting metabolic profiles and rates.
2. CYP-dependent oxidation of TCE
The overall scheme of TCE metabolism through CYP-dependent oxidation is shown in Fig. 
1. Several of the resulting metabolites are chemically stable and have been detected in urine, 
as highlighted in Fig. 1. A summary of the major oxidative metabolites formed from TCE, 
their site of formation, the species (experimental animals, humans or both) in which they 
have been identified, and their systemic availability is included in Table 1 (top section). 
TCE metabolism by the oxidative pathway occurs predominantly in the liver [7]. Other 
tissues including the lungs [8-10], kidneys [11], and male reproductive organs [12, 13] are 
also sites of CYP-mediated TCE metabolism. Chemical stability of the metabolite is an 
important determinant of systemic availability and fate. Relatively stable TCE metabolites 
may be transported from their site of formation into the bloodstream and delivered to other 
potential target organs. Chemically unstable and reactive end-products of TCE metabolism, 
on the other hand, can largely react with DNA, proteins, and lipids near their site of 
formation.
2.1. TCE metabolites formed through the CYP-dependent oxidation pathway
The initial step in TCE metabolism is catalyzed by one of several CYP enzymes and yields a 
chemically-unstable cytochrome P450-bound intermediate (TCE-O-CYP) [14]. A large 
number of metabolites are formed from TCE-O-CYP through either non-enzymatic 
rearrangement or specific enzymatic reactions. Specifically, TCE-O-CYP can have one of 
three fates: (1) conversion to chloral (CHL), which is in equilibrium with chloral hydrate 
(CH); (2) TCE-epoxide (TCE-O); or (3) N-hydroxy-acetyl-aminoethanol. Although Miller 
and Guengerich [14, 15] initially posited that unbound TCE-O did not form to an 
appreciable extent, subsequent studies by Cai and Guengerich [16-19] demonstrated that 
TCE-O is in fact generated. These results are consistent with the studies of Forkert [20] on 
1,2-dichloroethylene metabolism in mouse Clara cells, which demonstrated formation of an 
epoxide by a CYP-dependent reaction.
The majority of the flux in CYP-dependent oxidation of TCE is towards CHL/CH [21] via 
chlorine migration in an oxygenated TCE-CYP transition state [14]. In fact, CHL/CH is 
typically the most proximal stable metabolite recovered in incubations of tissues, cells, or 
microsomes with TCE [22]. CHL/CH undergoes either a reduction by alcohol 
dehydrogenase (ADH) [23] or CYP [24, 25] to generate trichloroethanol (TCOH). Oxidation 
of CHL/CH by aldehyde dehydrogenase (ALDH) results in formation of trichloroacetic acid 
(TCA) [26, 27]. Rapid metabolism of CHL/CH in the liver, where the enzymes that 
participate in further metabolism are abundant, likely explains its detection in smaller 
amounts than in other tissues (e.g., lung) [10]. TCA is typically the major metabolite of TCE 
that is recovered, although TCOH is also a significant metabolite. TCOH can be oxidized by 
CYPs to yield TCA [25], or can undergo glucuronidation by UDP-glucuronosyltransferases 
(UGTs) to produce trichloroethanol glucuronide (TCOG) [28]. Enterohepatic recirculation 
of TCOG/TCOH is also known to occur [29]. Both TCOH and TCOG are recovered in 
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urine. TCA may also undergo dechlorination to yield dichloroacetic acid (DCA) [30], albeit 
the relevance of these findings to in vivo metabolism has been questioned [31].
As illustrated in Fig. 1, there are several possible sources of DCA, including formation 
through the TCE-O intermediate. TCE-O spontaneously generates dichloroacetyl chloride 
(DCAC), a chemically unstable and reactive molecule, or oxalic acid (OA), a stable product 
that is excreted in urine. DCAC undergoes spontaneous dechlorination to produce DCA 
[32]. Past controversy and uncertainty about the accuracy of measurements of DCA 
formation highlight the complexity of the oxidative pathway. Conflicting results in the 
literature, some showing remarkably high levels of formation of DCA, led Ketcha and 
colleagues [33] to investigate and identify potential sources of artifacts. They concluded that 
the presence of strong acid in the assay solution causes dechlorination of TCA to DCA, thus 
overestimating the amount of DCA actually formed in vivo. In addition, kinetic analysis of 
blood levels of DCA and TCA following oral administration of TCE in the mouse also 
shows that TCA is not the only source of DCA in vivo [34, 35].
DCA has an extremely rapid disposition [36, 37] to glyoxylic, oxalic, and monochloroacetic 
acids. The major pathway for DCA biotransformation is complete dechlorination to 
glyoxylate in a reaction catalyzed by glutathione transferase ζ (GSTz) [38]. The glyoxylate 
is subsequently converted to oxalate, glycine, and CO2 [39]. DCA can also inactivate GSTz 
[40], which might lead to increased accumulation of DCA secondary to decreased 
elimination. Reductive monodehalogenation of DCA to monochloroacetic acid, albeit via an 
unknown in vivo mechanism, is a minor pathway that appears to increase with age in rats 
[41]. Interestingly, DCA is primarily metabolized by enzymes in the cytoplasm unlike other 
intermediates in the oxidative metabolism pathway (i.e., CH, TCOH, TCA), which are 
metabolized by enzymes localized primarily in mitochondria and endoplasmic reticulum 
[42]. Elimination rates of DCA in rats and mice have been reported to be approximately one 
order of magnitude higher than those in humans [43]. Nonetheless, the U.S. EPA [2] 
concluded that these may still be high enough in humans to prevent significant accumulation 
of DCA under most typical exposure conditions.
A third major metabolite postulated to be formed from TCE-O-CYP or TCE-O 
intermediates is N-hydroxy-acetyl-aminoethanol [7]. Although few studies have investigated 
this metabolite, N-hydroxy-acetyl-aminoethanol was found in urine of rats and mice 
administered TCE and it was estimated that it is formed in amounts greater than those of 
DCA [44].
2.2. Evidence for CYP-dependent oxidation of TCE in experimental animals
Considerably more data on oxidative metabolism of TCE are available from experimental 
animal models than from humans or human tissue. Among experimental animal species, 
studies in rats and mice are the most numerous. These studies have informed identification 
of the enzymes involved, potential sources of variability, and factors modulating 
metabolism. In particular, rodent studies have demonstrated the participation of several CYP 
enzymes in TCE metabolism, including hepatic CYP2E1, CYP1A1/2, CYP2B1/2, and 
CYP2C11 [45-48]. Forkert et al. [9] also found mouse recombinant CYP2F2 to be active in 
TCE metabolism. Among several recombinant CYPs tested, rat CYP2E1 exhibited the 
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highest catalytic efficiency for metabolism of TCE to CH (Vmax/Km = 0.79) whereas that for 
recombinant mouse CYP2F2 was much lower (Vmax/Km = 0.11). Thus, although CYP2E1 is 
considered the primary CYP enzyme for TCE oxidation, other CYPs may play a role, 
particularly at higher TCE concentrations or in specific extrahepatic tissues. Studies by Kim 
and Ghanayem [49] with CYP2E1 knockout mice confirmed the predominance of this 
specific CYP enzyme in TCE metabolism, but also indicated that other CYPs can catalyze 
TCE oxidation. Although TCE was metabolized to CH in the CYP2E1 knockout mice, it is 
difficult from these data to extrapolate to normal animals and quantify the role of other 
CYPs when CYP2E1 is present.
Studies from several in vitro incubations with tissue homogenates clearly illustrate the 
presence of species-dependent differences in TCE oxidative metabolism. For example, the 
maximal rate of CYP-dependent oxidative metabolism of TCE is 2- to 4-fold faster in mice 
than in rats; in humans, the maximal rate of CYP-dependent oxidative metabolism of TCE is 
5- to more than 10-fold slower than in rats [37, 50-52]. Maximal rates of TCE oxidative 
metabolism in rodents also differ between males and females. For example, Lash et al. [53] 
found higher concentrations of CYP-derived metabolites of TCE (i.e., CH, TCA, TCOH) in 
livers of males than in females; the opposite pattern, however, was observed in kidneys. 
These results are consistent with higher maximal rates of CYP-dependent metabolism and 
overall metabolic clearance of TCE in male rats.
The potential role for variability in CYP activity, due to genetic polymorphisms or drug-
drug interactions, in TCE metabolism has received some attention. Variability due to CYP 
polymorphisms has been suggested to have little impact on total flux of TCE metabolism for 
exposures below saturation, at which hepatic blood flow is limiting [2, 55]. As noted above, 
knockout of CYP2E1 in the mouse [49] does alter, but not completely abolish, liver CYP-
dependent TCE metabolism. However, CYP2E1 knockout had no effect on TCE toxicity in 
the lung [8]. Considerable inter-strain variability in formation of TCE metabolites from 
CYP-mediated oxidation of TCE has been also reported [56]. TCE (2100 mg/kg) was 
administered by intragastric lavage in corn oil to one hybrid and 14 inbred mouse strains; 
key metabolites were measured at 2, 8 and 24 h in serum. At the 8-h time point (time of 
maximal metabolite levels in serum), TCA concentrations varied 4.5-fold (from 
approximately 400 to 1800 nmol/ml) whereas DCA concentrations varied more than 100-
fold (from approximately 0.015 to 2 nmol/ml).
Modulation of metabolic conditions with CYP inducers or inhibitors, or alterations in 
competing pathways, can significantly influence CYP-dependent metabolism of TCE [57]. 
For example, CYP2E1 induction by pyridine markedly increased TCE metabolism in both 
kidney and liver cells while attenuation of CYP activity with either a CYP2E1-specific 
(diethyldithiocarbamate) or a broad-spectrum CYP (metyrapone) inhibitor decreased CYP-
dependent TCE metabolism but enhanced GSH conjugation of TCE. While such 
modulations of CYP activity may not significantly impact the total metabolic flux, they can 
alter the balance between oxidation and GSH conjugation, as well as metabolism in extra-
hepatic tissues that are not flow-limited. Such impacts may also be even more substantial at 
higher substrate concentrations, where the Vmax may become more limiting than hepatic 
blood flow.
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2.3. Evidence for CYP-dependent oxidation of TCE in humans
The major oxidative metabolites of TCE, TCA, and TCOH or TCOG, have been detected in 
human studies in both blood and urine, providing empirical evidence of in vivo TCE 
oxidation in humans [58-63]. Limited information about CYP enzymes involved and their 
tissue distribution is available from human studies. CYP2E1 is the major CYP enzyme from 
human liver microsomes that metabolizes organic solvents, including TCE, vinyl chloride, 
ethylene dichloride, and others [46]. Besides CYP2E1, the other human CYP enzymes 
reported to have some activity with TCE as substrate include CYP1A1/1A2, CYP2A6, and 
CYP3A4. There is some disagreement regarding the role of CYP3A4 as Hissink et al. [64] 
did not detect measurable metabolism of TCE with purified human CYP3A4. Typical 
activity of CYP2E1 towards TCE is approximately 2-fold and 200-fold higher than that of 
CYP1A2 and CYP3A4, respectively [7].
CYP distribution may be one factor in determining species-specific differences in TCE 
metabolism. Although CYPs are distributed in many extrahepatic tissues, the distribution is 
not uniform across species in terms of either enzyme expression or activity. For example, 
while CYP2E1 is highly expressed in human liver and testes [12], it is expressed at very low 
levels in human kidney [65]. Although previous studies [11, 66, 67] detected neither 
CYP2E1 expression nor its activity in human kidney, use of a newly developed ELISA 
method showed human kidney cortex to contain about 15% of the level of CYP2E1 in 
human liver when normalized to microsomal protein (30-122 pmol CYP2E1/mg microsomal 
protein in liver vs. 5.0-22 pmol CYP2E1/mg microsomal protein). Moreover, when tissue 
weight and microsomal protein content are factored in, the total amount and activity of 
CYP2E1 in human liver is more than 50-fold higher than those in human kidney cortex. This 
sharply contrasts with the situation in rat kidney, which contains easily detectable levels of 
CYP2E1 and exhibits a relatively high rate of CYP2E1-dependent metabolism of TCE to 
CH, TCA, and TCOH [68]. Hence, development of physiologically-based pharmacokinetic 
(PBPK) models for humans must take such significant species-dependent differences into 
account. Lipscomb et al. [69] modelled data on TCE oxidative metabolism in human liver 
microsomes and extrapolated rates in this in vitro system to account for total TCE 
metabolism in the human body. They concluded that the extrapolation modestly 
underestimated total metabolism and recommended inclusion of extrahepatic CYP-
dependent metabolism to increase the predictive value of the modelling approach. Similar 
conclusions were drawn from a Bayesian PBPK model-based analysis of toxicokinetic data 
on TCE metabolism in mice, rats and humans [70].
2.4. Mutagenic potential of TCE metabolites formed through CYP-dependent oxidation
The chemical reactivity and instability of TCE-O-CYP, TCE-O and DCAC suggest that 
adduction reactions with biological targets are likely. Indeed, irreversible binding of TCE 
metabolites from CYP-dependent oxidation to proteins and nucleic acids has been reported 
in a number of studies [15, 71, 72]. Additionally, studies of TCE genotoxicity in the liver, 
where oxidative metabolism would presumably predominate, are informative of the 
genotoxic potential of CYP-derived metabolites. For instance, Chang et al. [73] failed to 
detect any DNA single-strand breaks in the livers of rats at 4 h after single doses of 1-10 
mmol/kg of TCA, DCA, or monochloroacetate (MCA). However, they did detect small 
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increases in the amounts of DNA single strand breaks (approximately 7%) at 4 h in the 
livers of mice given the highest doses of TCA (10 mmol/kg) or DCA (5 or 10 mmol/kg). In 
contrast, Leavitt et al. [74] reported a 1.3- or 2.3-fold increase in mutant frequency in 
transgenic B6C3F1 mice harbouring the bacterial lacI gene after continuous exposure in the 
drinking water for 60 weeks to 1.0 or 3.5 g DCA/l, respectively. H-ras codon 61 mutations 
distinct from those in spontaneous tumors were found in mouse liver tumors following DCA 
administration in the drinking water (1.0 or 3.5 g/l), whereas those following TCA 
administration in the drinking water (4.5 g/l) exhibited the same mutational spectra as 
spontaneous tumors [75]. Mixed results are available for genotoxicity of TCE in mammalian 
cells in vitro [76]. One study in human lymphoblasts reported no DNA strand breaks after 
treatment with either MCA, DCA, TCA, or any of the corresponding aldehydes [73].
Numerous studies have also directly evaluated potential genotoxicity and mutagenicity of 
TCE metabolites formed through CYP-dependent oxidation, such as CH/CHL, DCA, TCA 
and, to a lesser extent, TCOH. Strong evidence is available to suggest that CH/CHL may be 
genotoxic and mutagenic. The evidence is from both in vivo and in vitro tests, in mammalian 
and other experimental systems, including studies with and without metabolic activation [2, 
76]. The types of damage reported include mutations, chromosomal aberrations, 
micronuclei, and cell transformation. Importantly, micronuclei in peripheral blood 
lymphocytes isolated from infants administered CH crystals mixed in breast milk or formula 
as a single dose of 50 mg/kg of body weight for sedation were significantly increased, 
consistent with the conclusion that CH is genotoxic in humans [77].
Evidence for other oxidative metabolites suggests a more limited mutagenic potential. The 
evidence that DCA may be genotoxic is weak to moderate. In bacterial and fungal test 
systems, only substitution mutation assays were positive [78]. TCA is generally regarded as 
not genotoxic. TCA was found to be overwhelmingly negative in bacteria and fungi [79, 80], 
in cultured human lymphocytes or lymphoblasts [73, 81], or in mammalian in vitro studies 
[82, 83]. Most animal in vivo studies found no evidence of genotoxicity of TCA [73, 81, 84, 
85]. The mutational profile of mouse liver tumors following TCA administration is no 
different from those in spontaneous liver tumors in the same strain [75, 86]. TCOH has not 
been evaluated in most recommended genotoxicity screening assays and thus the data should 
be interpreted with caution. One study found that TCOH was mutagenic in the presence of 
metabolic activation [87]; however, other studies were negative [80, 88].
3. GSH conjugation of TCE
TCE metabolism by the GSH conjugation pathway (Fig. 2) is initiated by the action of GSH 
S-transferase (GST) enzymes. The first step in this pathway is an SN2 nucleophilic 
displacement reaction of TCE with GSH, releasing Cl- ion and S-(1,2-
dichlorovinyl)glutathione (DCVG) as products. Although this initial GSH conjugation step 
can occur in many tissues, it occurs primarily in the liver owing to first-pass metabolism and 
the high content of GSTs. In the human and rat liver, the various GST isoforms can account 
for as much as 5% of total cytosolic protein [89]. Subsequent metabolism through the GSH 
conjugation pathway occurs primarily in the kidneys [7]. A summary of the site of formation 
and systemic availability of the major metabolites from the GSH-conjugation pathway is 
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presented in Table 1 (bottom section). As noted above, although quantitatively the liver is 
the primary site of GSH conjugation of TCE in the body, the liver is very efficient at 
excreting GSH conjugates into either bile or plasma. Subsequently, through enterohepatic 
and renal-hepatic circulation, generally either the cysteine conjugate DCVC or the 
mercapturate NAcDCVC is delivered to the kidneys for further metabolism or excretion. 
Additionally, in situ GSH conjugation of TCE can occur within the kidneys themselves, 
primarily the proximal tubules [90-92], establishing an intra-organ cycle of GSH conjugate 
transport and metabolism (Fig. 3).
3.1. TCE metabolites formed through the GSH conjugation pathway
DCVG, whether formed within the kidneys or in the liver, is processed predominantly in the 
kidneys by a sequence of two hydrolytic enzymes on the proximal tubular brush-border 
membrane, γ-glutamyltransferase (GGT) and cysteinylglycine dipeptidase (DP), to yield the 
corresponding cysteine conjugate, S-(1,2-dichlorovinyl)-L-cysteine (DCVC) [93]. DCVC 
was first discovered more than 50 years ago in soybean meal as a by-product of TCE 
extraction [94]. It was identified as the agent causing nephrotoxicity and aplastic anemia in 
cows, but only nephrotoxicity in most other species. Lock and colleagues [95] verified that 
DCVC indeed produced both nephrotoxicity and aplastic anemia in cattle, but further 
showed that none of the other haloalkenyl cysteine conjugates studied caused aplastic 
anemia in addition to the characteristic nephrotoxicity.
DCVC can be viewed as a major branch point in this metabolic pathway, as it can have three 
possible fates [7, 96]. First, DCVC can be N-acetylated by the microsomal cysteine 
conjugate N-acetyltransferase (NAT) to form the mercapturate N-acetyl-S-(1,2-
dichlorovinyl)-L-cysteine (NAcDCVC) [97]. Besides excretion into urine, NAcDCVC can 
be deacetylated within the renal proximal tubular cell by aminoacylase III to re-form DCVC 
[98-100]. Additionally, mercapturates of several nephrotoxic haloalkenes, including 
NAcDCVC, are substrates for CYP3A enzymes to yield sulfoxides [101-103]. Thus, 
although NAcDCVC is considered a stable end-product of TCE metabolism and is 
recovered in urine, it can undergo additional metabolic transformations that serve to 
reactivate it. These additional fates of the putative end-product of the GSH conjugation 
pathway highlight both the complexity of TCE metabolism by this pathway and the potential 
difficulties in using urinary NAcDCVC as a surrogate measurement for overall flux through 
the GSH conjugation pathway.
Second, DCVC can be a substrate for cysteine conjugate β-lyase (CCBL) activities to 
generate the reactive S-(1,2-dichlorovinyl)thiol (DCVT). DCVT spontaneously rearranges to 
form either chlorothioketene (CTK) or chlorothionoacetyl chloride (CTAC) [104, 105]. Both 
of these species are chemically unstable and reactive and are believed to be responsible for 
formation of covalent adducts derived from DCVC with nucleic acids [106], proteins [107], 
and phospholipids [108]. CCBL activity has been detected not only in the kidneys, but in 
liver and other tissues as well. Only renal, as opposed to extra-renal, CCBL activity is 
toxicologically important for kidney toxicity because of the tissue localization of plasma 
membrane transporters and several of the enzymes of the GSH conjugation pathway that 
determine the distribution of TCE metabolites [109]. The overall β-lyase reaction 
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mechanism is cleavage of a C-S bond to yield a reactive, thioacylating species. However, 
subsequent studies [110, 111] showed that the reaction mechanism can occur by either direct 
β-elimination or transamination with a suitable α-keto acid co-substrate to yield either the 
thiolate or a propionic acid derivative, respectively. The latter is chemically unstable and 
rearranges to release the thiolate. According to Cooper and colleagues [112, 113], many 
distinct mammalian enzymes are known to be capable of catalyzing the CCBL reaction. 
Some of the CCBL enzymes catalyze both β-elimination and transamination reactions, 
whereas others can only catalyze the former reaction. The relative importance of each of 
these activities in DCVC bioactivation, however, is not presently known.
Third, DCVC can be a substrate for the flavin-containing monooxygenase (FMO), yielding a 
reactive S-(1,2-dichlorovinyl)-L-cysteine sulfoxide (DCVCS) [114]. The FMOs, like the 
CYPs, represent a multigene family of enzymes [115]. Both enzyme systems also share 
several other characteristics, including localization in the endoplasmic reticulum, 
requirement for NADPH as a reductant, and overall catalysis of a mixed-function oxidation 
reaction. Differences do exist, however, that make some of the functions of the FMOs rather 
distinctive. For example, although there are more than 50 individual functional CYP 
enzymes from > 40 gene families in humans [116], there are only 5 FMO genes in 
mammals. FMOs catalyze oxidation of sulfur-, selenium-, and nitrogen-containing 
chemicals [117]. Although FMOs and some CYPs share substrates and catalyze the same 
overall reactions, FMOs have some distinctive substrates, including cysteine S-conjugates of 
various haloalkenes and haloalkanes.
Because of the reactive nature of the various intermediates from this pathway, only 
NAcDCVC has been recovered in urine of both experimental animals [62, 118] and humans 
[62, 63] exposed to TCE or DCVC. Of the two possible bioactivation pathways for DCVC, 
the CCBL and FMO reactions, the former has received the most attention and is thought to 
account for most of the bioactivation activity for DCVC [7].
3.2. Evidence for GSH conjugation of TCE in experimental animals
Evidence for function of the GSH-dependent pathway in vivo in experimental animals 
comes from detection of either NAcDCVC in urine, or DCVG and DCVC in blood, serum 
or target tissues, primarily liver and kidney. Bernauer et al. [62], Commandeur and 
Vermeulen [119], and Larson and Bull [37] reported NAcDCVC in the urine of rats dosed 
with TCE. As with the case in humans exposed to TCE [62, 63, 120], the ratio of oxidative 
metabolites of TCE (primarily TCA and TCOH/TCOG) to NAcDCVC was > 1000:1.
DCVG (up to 75 pmol/g liver) and DCVC (up to 400 pmol/g kidney) were detected in 
female, but not male, F344 rats administered TCE at up to 15 mmol/kg (1.97 g/kg) body 
weight by corn oil oral gavage [53]. The absence of detectable DCVG in liver or kidney of 
male rats is consistent with faster breakdown of DCVG in male rats than in female rats. 
DCVC, in contrast, was detected at levels of 5 to 9 pmol/g liver in female rats, 10 to 25 
pmol/g liver in male rats, 7 to 22 pmol/g kidney in female rats, and was not detectable in 
kidney tissue from male rats. DCVG was detected in whole blood of both male and female 
rats at levels ranging from 10 to 60 pmol/ml in males and 25 to 95 pmol/ml in females. 
DCVC was below the limit of detection in blood.
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Rusyn and colleagues [34, 35] detected both DCVG and DCVC in serum at levels as high as 
~ 40 pmol/ml and 2.4 pmol/ml, respectively, in two studies of male B6C3F1 mice 
administered 2.1 g TCE/kg body weight by oral gavage. The amounts of serum DCVG in 
mice were very similar to those reported by Lash et al. [53] in rats. The ability of Kim et al. 
[34, 35] to detect DCVC at low levels, < 10% of those of DCVG, was achieved through the 
development of new, highly sensitive detection methods. The studies in rats and in mice 
provide clear in vivo evidence of function of the GSH-conjugation pathway for TCE 
metabolism. A follow-up study in a panel of 15 inbred mouse strains showed that DCVG 
levels in serum vary among strains and that DCVG is more abundant than DCVC [56]. 
Serum DCVG levels were below the limit of detection in 4 strains and varied between 2 and 
40 pmol/ml in the other 11 strains. For DCVC, serum concentrations of this penultimate 
nephrotoxic and nephrocarcinogenic metabolite were below the limit of detection in 6 
strains and varied between 1.5 and 3 pmol/ml in other strains.
While occurring in many tissues, the initial step in the GSH conjugation pathway, catalyzed 
by GST, is most rapid in liver. Lash et al. [92] compared rates of DCVG formation in 
incubations of 1 or 2 mM TCE with 5 mM GSH in suspensions of isolated hepatocytes and 
isolated renal proximal tubular cells from male F344 rats. Rates were about 20-fold higher in 
hepatocytes (5 to 10 nmol DCVG formed/106 cells per 60 minutes) than in kidney cells (0.3 
to 0.5 nmol DCVG formed/106 cells per 60 minutes). Rates of GSH conjugation of TCE 
were also analyzed in liver and kidney microsomes and cytoplasm from male and female 
F344 rats and B6C3F1 mice to identify species-, sex-, and tissue-dependent differences. The 
rate of GSH conjugation of TCE was found to be markedly higher in mouse compared with 
rat tissues, modestly higher in male compared with female tissues and subcellular fractions, 
and markedly higher (5- to 25-fold) in liver than in kidney in the corresponding species and 
sex.
Several families of GST isoenzymes are expressed in mammalian tissues and little 
information is available concerning substrate specificity of each isoenzyme in general or 
with regard to TCE. Cummings et al. [121] investigated the GST isoform specificity towards 
TCE in renal cortical cytoplasm of male F344 rats. Using polyclonal antibodies specific to 
each isoform, they found that of the three classes of GSTs, only GSTα was detectable. 
Hence, only activity of the three GSTα dimers, GSTα1-1, GSTα1-2, and GSTα2-2, were 
assessed using GSTα isoform-selective inhibitors in isolated renal proximal tubular cells and 
purified GSTα1-2 isoforms. While all three specific GSTα enzymes exhibited similar Vmax 
towards TCE (75-150 pmol DCVG formed/min per mg protein), GSTα2-2 had a 50- to 100-
fold higher affinity (Km = 0.074 mM TCE with 5 mM GSH as co-substrate) than GSTα1-1 
or GSTα1-2 (Km = 3.99 and 7.51 mM, respectively). Studies with selective GST isoform 
inhibitors in renal proximal tubular cells, however, suggested that GSTα1-1 is the primary 
isoform that is functional in GSH conjugation of TCE in the intact rat kidney cell. These 
results contrast with those of Hissink et al. [64], who assessed the potential role of different 
GST isoforms in TCE metabolism by characterizing activity with several purified rat and 
human GSTs. They reported no activity for GSTα (GSTA) isoforms and significant activity 
with both GSTμ (GSTM) and GSTπ (GSTP) isoforms. Interestingly, these investigators 
measured DCVG formation at TCE concentrations ranging from 55 μM to 1 mM but 
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observed no saturation and reported activity of rat GSTμ3-3 with 0.25 mM TCE as substrate 
of only ~ 15 pmol/min per mg protein. Thus, it remains unclear which specific GST isoform 
is responsible for GSH conjugation of TCE.
DCVC metabolism by enzymes that possess CCBL activity can occur in either the 
cytoplasm or mitochondria. Studies of the CCBL-catalyzed reaction in vitro in kidney 
preparations, with DCVC as a substrate, show that in the rat this reaction is 3- to as much as 
10-fold higher than that in analogous human kidney models [97, 110, 111, 122-128]. Rates 
of CCBL-dependent metabolism of DCVC in rats are considerably slower than those for the 
initial GSH conjugation step that yields DCVG, suggesting that the CCBL-mediated 
bioactivation reaction is rate-limiting for the conversion of TCE to nephrotoxic and/or 
mutagenic metabolites. Although DCVC-induced nephrotoxicity has been studied in mice, 
metabolic rates for CCBL for that species are not available in the literature.
The precise function of each of the various CCBLs in rat kidney in DCVC bioactivation is 
unclear. For example, although many studies have focused on CCBL/glutamine 
transaminase K (GTK) in renal cytoplasm as the enzyme responsible for CCBL-dependent 
metabolism of DCVC in that subcellular fraction [111, 125, 126, 128, 129], Cooper et al. 
[130] suggested that a high-molecular-weight enzyme (MW = 330 kDa) is actually 
responsible for most of the observed metabolic activity in the renal cytoplasm. There are 
also questions about the precise suborganellar localization of renal mitochondrial CCBL 
activity [126, 127] and the functional importance of several mitochondrial proteins 
possessing CCBL activity [126, 127, 131-135].
The other major enzyme system responsible for bioactivation of DCVC is the FMO system. 
Elfarra and colleagues [136-139] characterized the activity of what was initially detected as 
a cysteine conjugate S-oxidase and later determined to be a catalytic function of FMOs. 
Although several FMOs are expressed in rat kidney, FMO3 is the only isoform with 
significant activity for sulfoxidation of DCVC [136].
3.3. Evidence for GSH conjugation of TCE in humans
In a case report describing TCE ingestion in a 17 year old male attempting suicide, the 
mercapturate N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NAcDCVC) was detected in urine, 
as were prominent CYP-derived metabolites, confirming function of the GSH-conjugation 
pathway for TCE metabolism in humans [90]. Quantitatively, the amount of recoverable 
NAcDCVC in urine of occupationally exposed workers is several orders of magnitude lower 
than that of TCA, the major urinary metabolite derived from the oxidative pathway [62, 63]. 
As noted above, because metabolites of the GSH-conjugation pathway are predominantly 
chemically reactive and unstable, measurement of NAcDCVC in urine indicates that flux 
through the pathway has occurred but does not provide an accurate quantitation of that flux. 
Goeptar et al. [122], Green et al. [97], and Bloemen et al. [140] used the higher ratio of TCA 
to NAcDCVC in urine and higher measured rates of CYP- versus GST-dependent 
metabolism in human liver samples to support conclusions that the GSH-conjugation 
pathway is a minor pathway in humans and that it is not toxicologically important. This 
conclusion has been challenged because of the consideration discussed above of the reactive 
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nature of metabolites derived from the GSH-conjugation pathway, and given other data on 
human metabolism of TCE as discussed below.
Besides detection of the mercapturate in urine as an indicator of exposure to TCE, DCVG 
was detected in the blood of human volunteers exposed by inhalation to either 50 ppm or 
100 ppm TCE for 4 hours [120]. Additionally, peak levels of and the area-under-the-curve 
(AUC) for DCVG were approximately 2-fold higher in males than in females, suggesting 
that males experience a higher exposure to reactive metabolite at a given dose of TCE and 
may be more susceptible to injury. Detection of this key intermediate in blood is consistent 
with what is known about the handling of GSH and GSH S-conjugates among tissues, a 
process referred to as “inter-organ metabolism” [141, 142] (Fig. 3).
There has been disagreement in the literature about the activity of GSH conjugation of TCE 
in human and rodent liver and kidney. Lash et al. [143] performed detailed kinetic analyses 
of GSH conjugation of TCE for human liver and kidney subcellular fractions in isolated 
hepatocytes and hepatic and renal cytoplasm and microsomes from humans. They reported 
rates and kinetics of DCVG formation that were generally in agreement with those reported 
for similar substrates by others. In contrast, Green et al. [97] reported rates of DCVG 
formation in human liver cytoplasm in vitro to be four orders of magnitude lower but did not 
perform detailed analyses of kinetics. Potential explanations for the differences relating to 
incubation conditions and analytical methods have been posited, but the controversy remains 
unresolved.
Four major GST isoforms are expressed in humans, GSTA, GSTM, GSTP, and GSTT 
[144-148]. Little information is available about the isoform specificity towards TCE, 
although Hissink et al. [64] reported similar values for purified human GSTM1-1 and 
GSTP1-1 and no activity with either purified human GSTA1-1, GSTA2-2, or GSTT1-1. 
Cummings et al. [66] reported that GSTA, GSTP, and GSTT, but not GSTM, proteins are all 
expressed in freshly isolated human proximal tubular cells. Interestingly, although only a 
limited number of human kidney samples were tested, both GSTA and GSTP protein 
expression exhibited a wide variation, consistent with the existence of genetic 
polymorphisms. In contrast, GSTT protein expression levels were nearly identical in all the 
samples. It is important, however, to determine if similar variations also exist in GST 
isoform expression in human liver as the liver is quantitatively the primary site of GSH 
conjugation of TCE.
Metabolism of DCVG to DCVC occurs in two steps, neither of which is rate-limiting for the 
overall flux through the GSH-conjugation pathway. Although humans have significantly 
lower GGT activity than rodents [149], GGT and DP activity on the brush-border plasma 
membrane of the proximal tubule of human kidney still far exceed that needed to metabolize 
even very high doses of DCVG. Thus, it is activity of the three enzymes that may 
subsequently act on DCVC, the CCBL, FMO, or NAT that determines overall flux.
Lash et al. [123] purified CCBL activity from human kidney cytoplasm and found that the 
intrinsic activity of the human cytoplasmic GTK protein was only about 10% of that from 
rat kidney cortex cytoplasm. Similarly, McGoldrick et al. [124] measured CCBL activity in 
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primary cultures of proximal tubular cells from both rat and human kidney, and found 
activity in rat kidney cells to be threefold higher than that in human kidney cells. Studies in 
human kidney cytoplasm showed that CCBL activity towards DCVC occurred at a similar 
rate compared with other typical substrates [150] and that with a preparation of purified 
GTK from human kidney cytoplasm, was a modest substrate, exhibiting a nearly 3-fold 
higher rate than substrates like β-chloro-D,L-alanine and Se-methyl-L-selenocysteine but 
only about 35% of that of S-(1,1,2,2-tetrafluoroethyl)-L-cysteine [125]. Additionally, 
although transamination substrates like L-Phe, L-Gln, L-Met, or L-Leu exhibited 2- to 6-fold 
higher activity than transamination with DCVC, the rate of β-elimination with DCVC as 
substrate was much higher. Even though expression of CCBL/GTK was found in human 
kidneys [151], little information is available about the regulation or genetics of this enzyme 
or any of the other enzymes that may function as CCBLs. In a limited number of human 
kidney samples, however, McCarthy et al. [150] reported nearly fivefold inter-individual 
variation in rates of pyruvate formation, suggesting the possibility that genetic 
polymorphisms may also exist for the CCBL. Because of the function of CCBL activity in 
generating reactive, sulfur-containing metabolites from DCVC, this finding also suggests 
that such polymorphisms will be associated with differential mutagenic potentials.
Although metabolism by CCBL has received the most focus in studies of DCVC 
bioactivation, it may not be the most important pathway by which this occurs, at least in 
human kidney. Studies of DCVC metabolism and acute cytotoxicity in freshly isolated 
human proximal tubular cells [11] found little protection from toxicity by preincubation with 
the CCBL/GTK inhibitor aminooxyacetic acid (AOAA). This contrasts sharply with the 
situation in rat proximal tubular cells, where DCVC-induced cytotoxicity is almost 
completely prevented by pre-incubation with AOAA [126].
The alternate explanation for DCVC-induced cytotoxicity in human kidney cells is that 
FMO may play a more prominent role relative to CCBL whereas the reverse is likely true in 
rat kidney cells. While human kidney expresses FMO1, FMO3, and FMO5, the FMO1 
isoform is the most highly expressed of the three and DCVC is only a substrate for FMO3 
[152]. In fact, FMO1 expression averaged about 10-fold higher and FMO5 about 2.5- to 5-
fold higher than that of FMO3. Although the sulfoxide metabolite generated by the FMO 
reaction is extremely reactive [138], more study is needed to fully appreciate the role of this 
pathway in DCVC metabolism and toxicity in human kidney.
3.4. Mutagenic potential of TCE metabolites formed through GSH conjugation
TCE metabolism through GSH conjugation results in formation of several intermediates 
with mutagenic potential due to their instability and high reactivity. These include DCVT, 
CTK and CTAC (Fig. 2). Most of the experimental studies of genotoxicity and mutagenicity 
of GSH conjugation metabolites of TCE have been performed with DCVG, DCVC, DCVCS 
and NAcDCVC. Because traditional bacterial mutagenesis assays use liver-derived S9 
fraction to test bioactivation, data obtained from such studies are less informative than 
experimental evidence obtained with kidney homogenates or purified enzymes responsible 
for biotransformation of TCE to GSH conjugation-derived reactive electrophiles.
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One published report examined the mutagenicity of DCVG in S. typhimurium strain TA2638 
using kidney subcellular fractions for metabolic activation and the β-lyase inhibitor AOAA 
to inhibit genotoxicity [153]. DCVG exhibited direct-acting mutagenicity, with kidney 
mitochondria, cytoplasm, or microsomes enhancing the effects. The CCBL inhibitor 
diminished, but did not abolish the effects. Liver subcellular fractions did not enhance the 
mutagenicity of DCVG, consistent with kidney in situ metabolism playing a significant role 
in the genotoxicity of TCE metabolites through the GSH conjugation pathway.
DCVC has been the subject of numerous genotoxicity and mutagenicity studies. It was 
found to be mutagenic in S. typhimurium (strains TA100, TA2638, and TA98) using the 
Ames assay in the absence of S9 [154], and in S. typhimurium strain TA2638 with kidney 
subcellular fractions for metabolic activation [155]. A recent study confirmed these findings 
[156]. The genotoxicity of DCVC is further supported by the predominantly positive results 
in other available in vitro and in vivo assays. Unscheduled DNA synthesis was observed 
with DCVC treatment of Syrian Hamster fibroblasts [157] or LLC-PK1 cells [158]. 
Transformation of LLC-PK1 cells [159] or primary cultures of rat kidney cells [160] grown 
in the presence of DCVC was also reported. DCVC administered in vivo, in isolated 
perfused kidneys, and in isolated proximal tubules of albino male rabbits led to formation of 
DNA strand breaks [161]. In all the above studies, pretreatment with the CCBL inhibitor 
AOAA markedly diminished the mutagenic or genotoxic effect of DCVC, demonstrating the 
requirement for metabolism. In rats that were exposed orally to a single dose of DCVC (1 or 
10 mg/kg), no significant DNA damage in rat kidney proximal tubules was observed at the 
16-hour sampling time with either dose, or after 1 mg/kg DCVC at the 2-hour sampling time 
[162]. A statistically significant increase in percentage tail DNA 2 hours after treatment with 
10 mg/kg DCVC was found, despite the small number of animals at each dose and sampling 
time.
Mutagenicity of NAcDCVC was investigated in S. typhimurium strain TA2638, using 
kidney subcellular fractions for metabolic activation and AOAA to inhibit genotoxicity 
[158]. NAcDCVC exhibited direct-acting mutagenicity in the absence of exogenous 
metabolic activation, with kidney cytoplasm enhancing the effects and AOAA diminishing, 
but not abolishing the effects.
DCVCS was found to be weakly mutagenic in S. typhimurium strain TA100 in the Ames 
salmonella mutagenicity assay [156]. DCVCS mutagenic activity was approximately 700-
fold lower than that of DCVC.
4. Transport and inter-organ distribution of TCE metabolites
Membrane transport and inter-organ translocation processes are important determinants of 
delivery of metabolic intermediates to sites of further metabolism or toxicity, and thus 
influence tissue distribution and handling of TCE metabolites [109, 141, 142]. These 
processes play a critical role in target organ specificity of TCE-induced adverse effects. 
Several oxidative metabolites, including TCOH, exhibit complex time-dependent patterns 
consistent with enterohepatic circulation, with excretion of glucuronidated TCOH in bile, 
regeneration of free TCOH in the small intestine, and reabsorption of TCOH from the gut to 
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the liver [7, 54]. Metabolites derived from GSH conjugation are also thought to undergo 
transport and transformation across multiple organs, including the liver, kidneys, and small 
intestine (Fig. 3).
Although GSH conjugation of TCE occurs predominantly in the liver, it can also occur in 
the kidneys. Hepatic DCVG is efficiently exported into either bile or plasma by efflux across 
the canalicular plasma membrane or sinusoidal plasma membrane, respectively. Biliary 
DCVG is largely degraded by GGT and DP activity to yield DCVC. Through enterohepatic 
circulation, this DCVC is returned to the liver where it undergoes N-acetylation to form the 
mercapturate NAcDCVC. Hepatic NAcDCVC is then exported to the kidneys for excretion 
in the urine. Both hepatic DCVG that is exported to plasma and intra-renal DCVG are 
efficiently translocated to the active site of renal GGT on the proximal tubular brush-border 
membrane, where it is degraded to DCVC.
A detailed summary of specific carrier proteins and the role of these transporters in GSH 
metabolism and turnover, susceptibility of the proximal tubules to oxidative and toxicant 
stresses, and modulation in disease and other pathological processes has been recently 
published [141]. DCVG that is presented to the kidneys can either undergo glomerular 
filtration and enter the tubular lumen or be in the renal periplasmic space. The former is 
metabolized by GGT and DP just as in the biliary tract to generate DCVC, which is 
transported into the proximal tubular cell by amino acid transporters for further metabolism. 
Renal plasma DCVG can be a substrate for one of three putative carriers on the basolateral 
plasma membrane. Work by Lash and Jones [163, 164] defined the processes of basolateral 
GSH uptake, demonstrating energy-dependent and both Na+-coupled and Na+-independent 
transport. They further showed that, like many membrane transporters, these carriers have 
somewhat broad substrate specificities and can also transport various γ-glutamyl amino 
acids and GSH S-conjugates, including DCVG [165]. Although substrate specificity and 
energetics studies proposed the potential function of three basolateral membrane carriers, the 
sodium dicarboxylate carrier-3 (NaC3; Slc13a3) and the organic anion transporter 1 and 3 
(OAT1/3; Slc22a6/8), definitive evidence has only been obtained for the function of OAT3 
[166].
5. Variability in TCE metabolism and TCE metabolite transport
Besides species differences, another important consideration for TCE metabolism in humans 
is inter-individual variability, with potential influences on both oxidative and GSH 
conjugation metabolism pathways. Lipscomb and colleagues [167] reported 2- to nearly 4-
fold variations in CYP content and a 5-fold range of rates of oxidative metabolism of TCE 
in human liver microsomes. This was most closely correlated with expression of CYP2E1 
protein. Similarly, Elfarra et al. [50] reported a 4-fold variation in the rate of TCE 
metabolism to CH and TCOH in a limited number of samples of human liver microsomes. 
In addition to CYPs, particularly CYP2E1, overall metabolism of TCE by the oxidative 
pathway is also determined by expression and activity of ALDH and ADH (Fig. 1). Hence, 
variation in expression and/or activity of these enzymes may impact the rate at which TCE is 
cleared and converted to end-products such as TCOH, TCA, and DCA. The rate at which 
potentially mutagenic metabolites (i.e., N-hydroxy-acetyl-aminoethanol and DCAC) are 
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formed will also vary according to these factors, presumably leading to variations in toxic 
outcomes. Major (up to 10-fold) inter-strain variation in both CYP- and GST-mediated 
metabolism of TCE has also been reported in mice [56]. It is important to note, however, 
that the limitations on variations in bioactivation imposed by hepatic blood flow may 
dampen the effects of differences in enzyme expression [55]. Lipscomb and colleagues [55] 
developed a PBPK model for study of TCE metabolism and demonstrated that hepatic blood 
flow delivers substrates to the liver at rates that are generally slower than those of the 
bioactivation reactions, thereby limiting the impact of differences in rates of those reactions.
In humans, three major underlying causes contribute to variation in expression and/or 
activity of drug metabolism enzymes, such as CYP2E1, ALDH, and ADH. The first cause is 
the existence of genetic polymorphisms, inherited mutations in genes that result in altered 
expression levels and/or activity of enzymes in at least 1% of the population. The overall 
implication of such genetic variation is that individuals with altered levels of a given 
enzyme may exhibit altered susceptibility to toxic effects of a chemical that is metabolized 
by that enzyme as compared to the rest of the population who express normal levels of the 
protein. Cataloguing of such individual variation and modulation of drug levels to account 
for this in a therapeutic regimen is the basis for the current drive for so-called “personalized 
medicine.” For toxic chemicals such as TCE, application of these principles to human health 
risk assessment represents an important refinement whose potential is only recently being 
realized [168]. Bronley-Delancy et al. [26] investigated oxidative metabolism of TCE in 
cryopreserved human hepatocytes and found large inter-individual variation in kinetic 
parameters for TCOH and TCA formation. Cells were incubated with CH and Km values 
ranged between 0.001 to 2.44 mM for TCOH formation and 0.005 to 1.27 mM for TCA 
formation; similarly, Vmax values ranged between 0.54 and 222 nmol TCOH formed/min 
per mg protein and 0.14 to 158 nmol TCA formed/min per mg protein. No correlation was 
seen, however, between Vmax and ADH or ALDH genotype among the limited number of 
human liver samples. Polymorphisms in CYP2E1 are also known [169-171]. However, the 
potential impact of such polymorphisms on TCE metabolism was not investigated.
The second major underlying cause for human variation in drug metabolism enzyme 
expression and/or activity is the influence of prior or concurrent exposure to a chemical or 
drug that is a substrate for the enzyme in question. This exposure often results in either 
inhibition of activity or induction of enzyme expression. For example, ethanol is 
metabolized by CYP2E1, ADH, and catalase, and chronic exposure to ethanol leads to 
increased activity of CYP2E1 [172]. Such changes would be expected to increase 
metabolism of TCE.
The third major underlying cause of human variation in drug metabolism enzyme expression 
and/or activity is the existence of a disease or other chronic, pathological state. For example, 
chronic diseases such as diabetes modulate expression and activities of various drug 
metabolism enzymes and transporter proteins [173].
Genetic polymorphisms have also been identified for OAT1 and OAT3 [174-176]. Thus, 
different subpopulations of humans may have a markedly different capacity to accumulate 
DCVG or DCVC, thus altering their basic pharmacokinetics and susceptibility to 
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nephrotoxicity. A better understanding of the implications of genetic polymorphisms in the 
genes for membrane transporters is relevant not only to toxicants but to therapeutics as well 
[177]. Further, expression and function of OATs and other organic anion transporters have 
been shown to exhibit gender-dependent differences in both humans and experimental 
animals [178-181], suggesting that transport differences are another contributing factor to 
gender differences in susceptibility to TCE metabolites. Protein kinase C or other signaling 
pathways can regulate gene expression or function of several of the organic anion 
transporters [182-184], adding another dimension to potential factors that can alter target 
cell accumulation of TCE metabolites.
6. Summary and conclusions
Despite nearly 40 years of research on the metabolism and target-organ toxicities associated 
with TCE, significant questions remain about how this environmental contaminant is 
handled in the body and its mechanisms of action in various target tissues. An appreciation 
of the chemical nature and reactivity of metabolites formed, how the enzymes involved are 
regulated, and tissue-, sex-, and species-specific differences are critical for understanding 
human health risks, including acute organ-specific toxicity, mutagenesis, and 
carcinogenesis. The complexities of TCE metabolism remain a continuing research 
challenge. Knowledge gaps persist regarding the extent of metabolism variability across 
target organs, species-, and individuals, including the amounts of reactive metabolites 
formed and their relative contribution to TCE-induced mutation and cancer.
There is consensus among experts that the CYP-mediated oxidation of TCE is a metabolic 
pathway that predominates quantitatively in all species studied, especially at 
environmentally-relevant concentrations or doses of TCE. Most of the TCE metabolites 
generated by the CYP-mediated oxidation pathway are chemically stable with evidence of 
systemic availability (Table 1) and urinary excretion (Fig. 1). With the exception of 
CHL/CH, these oxidative metabolites may contribute to carcinogenicity through 
mechanisms other than direct interaction with DNA. On the other hand, the high chemical 
reactivity and instability of metabolites generated by the GST pathway (Table 1 and Fig. 2) 
strongly argue for direct genotoxicity and mutagenicity as mechanistic events that may lead 
to cancer. A suggestion that the von-Hippel-Lindau tumor suppressor gene (VHL) mutations 
in renal cell carcinoma of subjects with occupational exposure to TCE are evidence of 
genotoxicity of TCE in humans [185, 186] has not been verified, and recent studies have 
reported VHL mutations with high frequency in renal cell carcinoma, irrespective of 
exposure to TCE and other chlorinated solvents [187, 188]. Still, recent molecular 
epidemiology data demonstrating elevated kidney cancer risks among GST-active 
individuals, and attenuation among GST-null individuals [189], strongly supports the 
conclusion that GSH conjugation of TCE is toxicologically significant, at least for the 
kidney as a target organ. Furthermore, the influence of these genetic polymorphisms adds an 
additional degree of complexity and uncertainty to understanding TCE-induced 
mutagenicity and carcinogenicity.
The quantitative extent of TCE flux through the GSH conjugation pathway remains 
uncertain. Difficulties in quantifying flux through pathways that generate reactive species 
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notwithstanding, new sensitive methods to quantify certain TCE metabolites are being 
developed and should help address remaining uncertainties in both human and experimental 
animal studies. Equally important is to determine the toxicity and mutagenicity of TCE 
metabolites from the GSH conjugation pathway in vivo. Few data are available from sub-
chronic or chronic experimental animal studies to inform adverse health outcomes of DCVG 
and DCVC.
An additional, important consideration for human health risk assessment is variability in 
rates of TCE metabolism across species, tissues and individuals. For species differences, 
rates of both CYP- and GST-dependent flux are faster in rodents than in humans, with those 
in mice generally being markedly faster than in rats. Knowledge of such species differences 
in metabolic rates is important in using data from experimental animals to make predictions 
for humans, although differences in rates may not translate into differences in total flux, due 
to other physiological factors such as hepatic blood flow. For tissue differences, although the 
liver is universally the primary site of TCE metabolism amongst all species studied, 
extrahepatic sites are important for many tissue-specific effects in several species (Fig. 3). 
For individual variability, genetic polymorphisms exist for CYP2E1, GSTs, CCBL, and 
FMO, which need to be taken into account when making predictions for humans. Likewise, 
considerable variability in TCE metabolism has been observed among mouse inbred strains 
and understanding whether the inter-strain variability in TCE metabolism is associated with 
the differences in toxicity outcomes may provide important clues as to the quantitative 
underpinnings of various toxic effects of TCE, including mutagenicity [190]. Finally, the 
complexities of using epidemiology studies for understanding TCE metabolism and 
mechanisms of action are illustrated by a recent retrospective cohort study [191].
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• Trichloroethylene is mutagenic and carcinogenic in humans and animals
• Trichloroethylene undergoes both cytochrome P450- and glutathione-dependent 
metabolism
• Glutathione-derived metabolites of trichloroethylene are mutagenic
• Species-, sex-, and tissue-dependent differences exist in trichloroethylene 
metabolism
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Fig. 1. Scheme for biotransformation of TCE by oxidative metabolism
TCE undergoes cytochrome P450 (CYP)-dependent oxidation to form either a TCE-CYP 
intermediate or an epoxide intermediate. Further processing through either non-enzymatic 
rearrangements or actions of aldehyde dehydrogenase (ALDH), alcohol dehydrogenase 
(ADH), CYPs, or GSH S-transferase zeta (GSTZ) yield a variety of metabolites, including 
chloral (CHL) and chloral hydrate (CH), dichloroacetate (DCA), trichloroacetate (TCA), 
trichloroethanol (TCOH) and its glucuronide (TCOG), monochloroacetate (MCA), and 
oxalate (OA). Names of metabolites that are recovered in urine are shown in boxes and 
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those that are chemically unstable or reactive are shown in brackets. Other abbreviations: 
TCE-O, trichloroethylene oxide; DCAC, dichloroacetyl chloride; N-OH-Ac-Aminoethanol, 
N-hydroxyacetyl aminoethanol; UGT, UDP-glucuronosyltransferase.
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Fig. 2. Scheme for biotransformation of TCE by the GSH conjugation pathway
TCE undergoes conjugation with GSH to yield the GSH S-conjugate DCVG. After 
processing to yield the cysteine S-conjugate DCVC, three potential fates are detoxication to 
yield the mercapturate NAcDCVC or bioactivation by either the cysteine conjugate β-lyase 
to yield dichlorovinylthiol, which rearranges to yield thioacylating species, or the flavin-
containing monooxygenase to yield DCVC sulfoxide. The mercapturate can also be 
deacetylated to regenerate DCVC or it can undergo CYP3A-dependent sulfoxidation. Names 
of metabolites that are recovered in urine are shown in boxes and those that are chemically 
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unstable or reactive are shown in brackets. Abbreviations: CYP3A, cytochrome P-450 3A; 
CTAC, chlorothionoacetyl chloride; CTK, chlorothioketene; DCVC, S-(1,2-dichlorovinyl)-
L-cysteine; DCVG, S-(1,2-dichlorovinyl)glutathione; DCVCO, DCVC sulfoxide; DCVT, 
1,2-dichlorovinylthiol; DP, dipeptidase; FMO, flavin-containing monooxygenase; GGT, γ-
glutamyltransferase; GSH, glutathione; GST, GSH S-transferase; NAcDCVC, N-acetyl-S-
(1,2-dichlorovinyl)-L-cysteine; NAcDCVCS, NAcDCVC sulfoxide; NAT, N-
acetyltransferase.
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Fig. 3. Inter-organ pathways for metabolism of TCE by the GSH conjugation pathway
The scheme summarizes the tissue localization of metabolic reactions and membrane 
transporters involved in whole body metabolism of TCE by the GSH conjugation pathway. 
Most of the DCVG formation occurs in the liver, which is very efficient at excreting it into 
bile or plasma. Biliary DCVG is processed to yield the cysteine conjugate DCVC, which 
then returns to the liver by enterohepatic recirculation. Most of the hepatic DCVC is N-
acetylated to form the mercapturate NAcDCVC, which is efficiently excreted into plasma. 
Plasma DCVG and NAcDCVC move through the blood and are extracted by the kidneys. 
DCVG formation also occurs, although to a lesser extent, within the kidneys themselves.
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Table 1
Summary of metabolite formation and systemic availability for TCE
Compound or
metabolite









































TCE metabolites through GSH conjugation pathway
DCVG Liver (A, H)Kidney (A, H) Yes









Kidney (A, H) Yes
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